Akouos, Inc.

Akouos, Inc. (AKUS) priced its initial public offering on Jun 26, 2020 at $17.00 per share, raising $212.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $552.2M. BofA Securities was lead-left underwriter, joined by TD Cowen, Piper Sandler and BTIG. WilmerHale advised the company and Cooley advised the underwriters.

Akouos, Inc. is a precision genetic medicine company developing gene therapies to restore, improve and preserve hearing in people with disabling hearing loss. Its platform uses a proprietary adeno-associated virus vector library and a novel delivery approach, and its lead product candidate is AK-OTOF.

Status

IPO

Ticker

AKUS

Exchange

Nasdaq Global Select

Priced

Jun 26, 2020

IPO price

$17.00

Raised

$212.5M

Market cap at IPO price

$552.2M

First filed

Jun 5, 2020

Underwriters

BofA Securities, TD Cowen, Piper Sandler and BTIG

Company counsel

WilmerHale

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.